PT  - JOURNAL ARTICLE
AU  - J M Grindel
AU  - R S Rozman
AU  - D M Leahy
AU  - N A Molek
AU  - H H Gillum
TI  - The absorption, distribution, and excretion in mice of a quinolinemethanol antimalarial, 2,8-bis(trifluoromethyl)-4-(1-hydroxy-3-(N-t-butylamino)propyl)quinoline phosphate (WR 184,806).
DP  - 1976 Mar 01
TA  - Drug Metabolism and Disposition
PG  - 133--139
VI  - 4
IP  - 2
4099  - http://dmd.aspetjournals.org/content/4/2/133.short
4100  - http://dmd.aspetjournals.org/content/4/2/133.full
SO  - Drug Metab Dispos1976 Mar 01; 4
AB  - Approximately 75% of the radioactivity derived from WR 184806-14C was excreted in the feces with the remainder in the urine after po administration. At least 77-85% of the dose was absorbed by 2-8 hr; lungs, liver, skeletal muscle, kidneys, small intestine (less contents) and residual carcass were major sites of deposition of total radioactivity. Within these tissues the radioactivity present was predominantly as WR 184,806 rather than its metabolites. Peak blood plasma levels of WR 184,806 occurred at 2-4 and 7-10 hr. The peak erythrocyte level of WR 184,806 occurred at 6 hr. The presence in the urine and feces of unchanged WR 184,806 was confirmed by thin-layer chromatography and inverse isotope dilution.